Eli Lilly Obesity Pill Keeps Weight Loss After Wegovy, Zepbound

Here’s a summary of the key‍ takeaways from the article about Eli‍ Lilly’s orforglipron:

* Orforglipron helps maintain weight loss: A late-stage⁤ trial showed that Eli⁢ Lilly’s oral GLP-1 pill, orforglipron, helped people maintain the⁣ majority of their weight ‍loss after switching from Zepbound or Novo Nordisk’s Wegovy.
* High Maintainance Rates: Patients switching from Wegovy regained roughly 2 pounds (95% maintenance), while those switching from Zepbound regained⁢ around 11 pounds (80% maintenance).
* FDA Approval Pending: Eli Lilly has filed for FDA approval and received a priority review voucher, potentially speeding up the approval process.
* Potential Role ⁣as Maintenance Therapy: The pill appears less effective ⁢for initial weight loss than injections, but it might very well be valuable as a convenient, needle-free option for maintaining weight loss long-term.
* Competition with novo Nordisk: Novo Nordisk is also developing an oral obesity drug, and is⁢ likely to enter the market first.
* Market Impact: Analysts believe the positive trial data could allow Eli lilly⁣ to gain market share from Novo Nordisk’s Wegovy.
* Stock Increase: ⁣ Eli Lilly’s shares rose ⁤over 2% following the announcement.

In essence, orforglipron ⁤isn’t necessarily a replacement for powerful weight loss injections, but a potential ⁢solution for people who want to stop ‍injections and avoid regaining weight.